肿瘤坏死因子α抑制剂及其他生物制剂相关矛盾性银屑病的临床研究进展

doi:10.35541/cjd.20210420

Abstract

Abstract: 【Abstract】 Tumor necrosis factor （TNF）-α inhibitors have become an important choice for patients with chronic inflammatory diseases who are intolerant or poorly responsive to conventional therapies. Studies have shown that psoriasis can develop or be exacerbated in 2% - 5% of patients treated with TNF-α inhibitors, and this phenomenon is called paradoxical psoriasis. Paradoxical psoriasis and classic psoriasis have similar clinical manifestations, but different immunological mechanisms. This review summarizes the pathogenesis, clinicopathological features and management of paradoxical psoriasis, and provides an overview of paradoxical psoriasis following the application of other common biological agents.

Key words: Psoriasis, Tumor necrosis factor-alpha, Biological agents, Drug toxicity, Paradoxical psoriasis

Lu Jiawei, Lu Yan. Paradoxical psoriasis induced by tumor necrosis factor-α inhibitors and other biological agents[J]. Chinese Journal of Dermatology, 2024, 57(5): 479-482.doi:10.35541/cjd.20210420

References ［40］

［1］	Bucalo A, Rega F, Zangrilli A, et al. Paradoxical psoriasis induced by anti⁃TNFα treatment: evaluation of disease⁃specific clinical and genetic markers［J］. Int J Mol Sci, 2020,21（21）:7873. doi: 10.3390/ijms21217873.
［2］	Cabaleiro T, Prieto⁃Pérez R, Navarro R, et al. Paradoxical psoriasiform reactions to anti⁃TNFα drugs are associated with genetic polymorphisms in patients with psoriasis［J］. Pharmacogenomics J, 2016,16（4）:336⁃340. doi: 10.1038/tpj. 2015.53.
［3］	Conrad C, Di Domizio J, Mylonas A, et al. TNF blockade induces a dysregulated type I interferon response without autoimmunity in paradoxical psoriasis［J］. Nat Commun, 2018,9（1）:25. doi: 10.1038/s41467⁃017⁃02466⁃4.
［4］	Fania L, Morelli M, Scarponi C, et al. Paradoxical psoriasis induced by TNF⁃α blockade shows immunological features typical of the early phase of psoriasis development［J］. J Pathol Clin Res, 2020,6（1）:55⁃68. doi: 10.1002/cjp2.147.
［5］	Aerts NE, De Knop KJ, Leysen J, et al. Increased IL⁃17 production by peripheral T helper cells after tumour necrosis factor blockade in rheumatoid arthritis is accompanied by inhibition of migration⁃associated chemokine receptor expression［J］. Rheumatology （Oxford）, 2010,49（12）:2264⁃2272. doi: 10. 1093/rheumatology/keq224.
［6］	Talotta R, Berzi A, Atzeni F, et al. Paradoxical expansion of Th1 and Th17 lymphocytes in rheumatoid arthritis following infliximab treatment: a possible explanation for a lack of clinical response［J］. J Clin Immunol, 2015,35（6）:550⁃557. doi: 10. 1007/s10875⁃015⁃0182⁃0.
［7］	Zou J, Rudwaleit M, Brandt J, et al. Down⁃regulation of the nonspecific and antigen⁃specific T cell cytokine response in ankylosing spondylitis during treatment with infliximab［J］. Arthritis Rheum, 2003,48（3）:780⁃790. doi: 10.1002/art.10847.
［8］	Moran B, Gallagher C, Tobin AM, et al. Enrichment of polyfunctional IL⁃17⁃producing T cells in paradoxical psoriasis skin lesions［J］. J Invest Dermatol, 2020,140（5）:1094⁃1097. doi: 10.1016/j.jid.2019.10.010.
［9］	Cohen JN, Bowman S, Laszik ZG, et al. Clinicopathologic overlap of psoriasis, eczema, and psoriasiform dermatoses: a retrospective study of T helper type 2 and 17 subsets, interleukin 36, and β⁃defensin 2 in spongiotic psoriasiform dermatitis, sebopsoriasis, and tumor necrosis factor α inhibitor⁃associated dermatitis［J］. J Am Acad Dermatol, 2020,82（2）:430⁃439. doi: 10.1016/j.jaad.2019.08.023.
［10］	Tillack C, Ehmann LM, Friedrich M, et al. Anti⁃TNF antibody⁃induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon⁃γ⁃expressing Th1 cells and IL⁃17A/IL⁃22⁃expressing Th17 cells and respond to anti⁃IL⁃12/IL⁃23 antibody treatment［J］. Gut, 2014,63（4）:567⁃577. doi: 10.1136/gutjnl⁃2012⁃302853.
［11］	Xueyi L, Lina C, Zhenbiao W, et al. Levels of circulating Th17 cells and regulatory T cells in ankylosing spondylitis patients with an inadequate response to anti⁃TNF⁃α therapy［J］. J Clin Immunol, 2013,33（1）:151⁃161. doi: 10.1007/s10875⁃012⁃9774⁃0.
［12］	Moy AP, Murali M, Kroshinsky D, et al. T⁃helper immune phenotype may underlie ′paradoxical′ tumour necrosis factor⁃α inhibitor therapy⁃related psoriasiform dermatitis［J］. Clin Exp Dermatol, 2018,43（1）:19⁃26. doi: 10.1111/ced.13227.
［13］	Nguyen DX, Ehrenstein MR. Anti⁃TNF drives regulatory T cell expansion by paradoxically promoting membrane TNF⁃TNF⁃RII binding in rheumatoid arthritis［J］. J Exp Med, 2016,213（7）:1241⁃1253. doi: 10.1084/jem.20151255.
［14］	Odai T, Matsunawa M, Takahashi R, et al. Correlation of CX3CL1 and CX3CR1 levels with response to infliximab therapy in patients with rheumatoid arthritis［J］. J Rheumatol, 2009,36（6）:1158⁃1165. doi: 10.3899/jrheum.081074.
［15］	Greisen SR, Schelde KK, Rasmussen TK, et al. CXCL13 predicts disease activity in early rheumatoid arthritis and could be an indicator of the therapeutic ′window of opportunity′［J］. Arthritis Res Ther, 2014,16（5）:434. doi: 10.1186/s13075⁃014⁃0434⁃z.
［16］	van Lieshout AW, Fransen J, Flendrie M, et al. Circulating levels of the chemokine CCL18 but not CXCL16 are elevated and correlate with disease activity in rheumatoid arthritis［J］. Ann Rheum Dis, 2007,66（10）:1334⁃1338. doi: 10.1136/ard.2006.06 6084.
［17］	Han BK, Kuzin I, Gaughan JP, et al. Baseline CXCL10 and CXCL13 levels are predictive biomarkers for tumor necrosis factor inhibitor therapy in patients with moderate to severe rheumatoid arthritis: a pilot, prospective study［J］. Arthritis Res Ther, 2016,18:93. doi: 10.1186/s13075⁃016⁃0995⁃0.
［18］	Goldminz AM, Suárez⁃Fariñas M, Wang AC, et al. CCL20 and IL22 messenger RNA expression after adalimumab vs methotrexate treatment of psoriasis: a randomized clinical trial［J］. JAMA Dermatol, 2015,151（8）:837⁃846. doi: 10.1001/jamadermatol.2015.0452.
［19］	Khanniche A, Zhou L, Jiang B, et al. Restored and enhanced memory T cell immunity in rheumatoid arthritis after TNFα blocker treatment［J］. Front Immunol, 2019,10:887. doi: 10.3389/ fimmu.2019.00887.
［20］	Murphy MJ, Cohen JM, Vesely MD, et al. Paradoxical eruptions to targeted therapies in dermatology: a systematic review and analysis［J/OL］. J Am Acad Dermatol, 2020:S0190⁃9622（20）33154⁃6［2021⁃06⁃01］. https://www.sciencedirect.com/science/article/pii/S0190962220331546?via%3Dihub. doi: 10.1016/j.jaad.2020.12.010.
［21］	Caldarola G, Pirro F, Di Stefani A, et al. Clinical and histopathological characterization of eczematous eruptions occurring in course of anti IL⁃17 treatment: a case series and review of the literature［J］. Expert Opin Biol Ther, 2020,20（6）:665⁃672. doi: 10.1080/14712598.2020.1727439.
［22］	Stoffel E, Maier H, Riedl E, et al. Analysis of anti⁃tumour necrosis factor⁃induced skin lesions reveals strong T helper 1 activation with some distinct immunological characteristics［J］. Br J Dermatol, 2018,178（5）:1151⁃1162. doi: 10.1111/bjd.16126.
［23］	Ishiuji Y, Umezawa Y, Asahina A, et al. Exacerbation of atopic dermatitis symptoms by ustekinumab in psoriatic patients with elevated serum immunoglobulin E levels: report of two cases［J］. J Dermatol, 2018,45（6）:732⁃734. doi: 10.1111/1346⁃8138. 14295.
［24］	Hu JZ, Billings SD, Yan D, et al. Histologic comparison of tumor necrosis factor⁃α inhibitor⁃induced psoriasis and psoriasis vulgaris［J］. J Am Acad Dermatol, 2020,83（1）:71⁃77. doi: 10. 1016/j.jaad.2020.01.006.
［25］	Navarro R, Villar⁃Zarra K, Juarez Á, et al. Histopathologic study of paradoxical psoriasis induced by antitumor necrosis factor alpha therapy: is it true psoriasis?［J］. J Cutan Pathol, 2021,48（6）:813⁃816. doi: 10.1111/cup.13919.
［26］	Benzaquen M, Flachaire B, Rouby F, et al. Paradoxical pustular psoriasis induced by ustekinumab in a patient with Crohn′s disease⁃associated spondyloarthropathy［J］. Rheumatol Int, 2018,38（7）:1297⁃1299. doi: 10.1007/s00296⁃018⁃4034⁃0.
［27］	Noell C, McQuade B, Gottlieb A, et al. Anti IL⁃17 flared psoriasis in a patient on secukinumab［J/OL］. Dermatol Ther, 2017,30（4）:e12505. doi: 10.1111/dth.12505.
［28］	Tadiotto Cicogna G, Messina F, Nalotto L, et al. Case report: paradoxical acrodermatitis of Hallopeau⁃like eruption following anti⁃IL⁃17 therapy［J］. F1000Res, 2019,8:336. doi: 10.12688/f1000research.18493.1.
［29］	Dogra S, Bishnoi A, Narang T, et al. Secukinumab⁃induced paradoxical pustular psoriasis［J］. Clin Exp Dermatol, 2019,44（1）:72⁃73. doi: 10.1111/ced.13731.
［30］	Hoshina D, Haga N, Furuya K, et al. Paradoxical localized exacerbation of psoriatic eruptions triggered by secukinumab［J］. Clin Exp Dermatol, 2018,43（6）:718⁃719. doi: 10.1111/ced. 13375.
［31］	Napolitano M, Caiazzo G, Fabbrocini G, et al. Increased expression of interleukin⁃23A in lesional skin of patients with atopic dermatitis with psoriasiform reaction during dupilumab treatment［J］. Br J Dermatol, 2021,184（2）:341⁃343. doi: 10. 1111/bjd.19459.
［32］	Mirza FN, Wang A, Ramachandran SM, et al. Dupilumab⁃induced phenotype switch from atopic dermatitis to psoriasis is characterized by de novo interleukin⁃17A expression: a case report［J］. Br J Dermatol, 2021,185（2）:432⁃434. doi: 10.1111/bjd.20064.
［33］	Hayakawa M, Izumi K, Higashida⁃Konishi M, et al. Tocilizumab⁃induced psoriasis⁃like eruption resolved by shortening the dose interval in a patient with rheumatoid arthritis: a case⁃based review［J］. Rheumatol Int, 2019,39（1）:161⁃166. doi: 10.1007/s00296⁃018⁃4175⁃1.
［34］	Matsushima Y, Hayashi A, Mizutani K, et al. Psoriasiform dermatitis developing during treatment of juvenile idiopathic arthritis with tocilizumab［J］. Case Rep Dermatol, 2019,11（3）:317⁃321. doi: 10.1159/000504429.
［35］	Zheng J, Gao Y, Ding Y. Successful management of infliximab⁃induced generalized pustular psoriasis without therapy discontinuation in a patient with psoriatic arthritis［J/OL］. Dermatol Ther, 2019,32（6）:e13132. doi: 10.1111/dth.13132.
［36］	Bruzzese V, Pepe J. Efficacy of cyclosporine in the treatment of a case of infliximab⁃induced erythrodermic psoriasis［J］. Int J Immunopathol Pharmacol, 2009,22（1）:235⁃238. doi: 10.1177/039463200902200126.
［37］	Mazloom SE, Yan D, Hu JZ, et al. TNF⁃α inhibitor⁃induced psoriasis: a decade of experience at the Cleveland Clinic［J］. J Am Acad Dermatol, 2020,83（6）:1590⁃1598. doi: 10.1016/j.jaad. 2018.12.018.
［38］	Koumaki D, Koumaki V, Katoulis A, et al. Adalimumab⁃induced scalp psoriasis with severe alopecia as a paradoxical effect in a patient with Crohn′s disease successfully treated with ustekinumab［J/OL］. Dermatol Ther, 2020,33（4）:e13791. doi: 10.1111/dth.13791.
［39］	Bonomo L, de Moll EH, Li L, et al. Tumor necrosis factor inhibitor⁃induced psoriasis in a pediatric Crohn′s disease patient successfully treated with ustekinumab［J］. J Drugs Dermatol, 2020,19（3）:328⁃331.
［40］	Li SJ, Perez⁃Chada LM, Merola JF. TNF inhibitor⁃induced psoriasis: proposed algorithm for treatment and management［J］. J Psoriasis Psoriatic Arthritis, 2019,4（2）:70⁃80. doi: 10.1177/2475530318810851.

[1]	Hu Mengyao, Li Min, Chen Sihan, Wei Xuecui, Chen Yujie, Xu Song, Chen Xu, . Different regulatory effects of S100A8/A9 expressed by keratinocytes in three common inflammatory skin injury modes [J]. Chinese Journal of Dermatology, 2024, 57(5): 435-444.
[2]	China Dermatologist Association, Combination of Traditional and Western Medicine Dermatology. Diagnosis and treatment of erythrodermic psoriasis: a Chinese expert consensus statement （2024） [J]. Chinese Journal of Dermatology, 2024, 57(5): 409-417.
[3]	Zhang Yuanwen, Sun Congqian, Pan Wendong. Off-label clinical application of botulinum toxin in dermatology [J]. Chinese Journal of Dermatology, 2024, 57(5): 471-475.
[4]	Guo Lan, Jin Hongzhong. Small-molecule/biological agents in the treatment of pruritus [J]. Chinese Journal of Dermatology, 2024, 57(5): 475-478.
[5]	Ding Rui, Zhang Weiliang, Li Jing, Chen Yujia, Li Junying. Dupilumab for the treatment of five cases of refractory endogenous hyperkeratotic hand-foot eczema [J]. Chinese Journal of Dermatology, 2024, 0(4): 20230429-e20230429.
[6]	Yue Shuzhen, Shu Ye, Luo Yangyang, Li Keyao, Zhang Yuanyuan, Tang Jianping, Wei Zhu. Efficacy and safety of omalizumab in the treatment of chronic urticaria in children: a retrospective study [J]. Chinese Journal of Dermatology, 2024, 57(4): 354-358.
[7]	Yan Rufan, Liao Jieyue, Guo Ziyu, Yao Nan, Zhou Wenyu, Luo Shuaihantian, Zhang Guiying, Zhao Ming. Pathogenesis and targeted therapy of pemphigus [J]. Chinese Journal of Dermatology, 2024, 57(4): 374-378.
[8]	Chen Xingyu, Yao Xu. Role of neutrophils in inflammatory dermatoses [J]. Chinese Journal of Dermatology, 2024, 0(3): 20220865-e20220865.
[9]	Wu Yubing, Wang Xiaoyu, An Binyi, Wu Yingying, Sang Hong, Kong Qingtao, . Role of cyclic guanosine monophosphate-adenosine monophosphate synthase-stimulator of interferon genes signaling pathway in the occurrence of psoriasis [J]. Chinese Journal of Dermatology, 2024, 0(3): 20230394-e20230394.
[10]	Zhu Tingting, Zhang Xuejun. Apremilast in the treatment of plaque psoriasis [J]. Chinese Journal of Dermatology, 2024, 0(3): 20230448-e20230448.
[11]	Hao Dan, Wang Yiyi, Xiao Yue, Yan Wei, Li Wei. Systemic treatment options for psoriasis in special areas [J]. Chinese Journal of Dermatology, 2024, 0(3): 20230190-e20230190.
[12]	Zong Yangyongyi, Ma Chujun, Su Zhonglan. Eczematization following the treatment of psoriasis with biological agents: pathogenesis and management [J]. Chinese Journal of Dermatology, 2024, 0(3): 20220578-e20220578.
[13]	Wang Yukun, Liu Jie. Application of deep learning in non-neoplastic dermatoses [J]. Chinese Journal of Dermatology, 2024, 0(3): 20220660-e20220660.
[14]	Yao Manxue, Zhou Naihui. Stevens-Johnson syndrome/toxic epidermal necrolysis associated with programmed death-1/programmed death-ligand 1 inhibitors [J]. Chinese Journal of Dermatology, 2024, 0(3): 20220644-e20220644.
[15]	Ye Hui, Xue Rujun, Zhang Xibao. Application of biological therapies and mechanisms of immunophenotypic switching in psoriasis and atopic dermatitis [J]. Chinese Journal of Dermatology, 2024, 0(3): 20220795-e20220795.

Paradoxical psoriasis induced by tumor necrosis factor-α inhibitors and other biological agents

PDF

PDF (Mobile)

Knowledge

Abstract

Cite this article

share this article

References ［40］

Related Articles 15

Metrics

Comments

Recommended 10